CONTINUE TO SITE
OR WAIT null SECS
- About Us
- Advertise
- Editorial
- Contact Us
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2025 MJH Life Sciences™ and Pharmaceutical Commerce. All rights reserved.
Embarking on the CAR-T Journey
Renier Brentjens, MD, PhD outlines the evolution of the space, while offering ways to boost patient access to these treatments.
In this exclusive PC Podcast interview, Renier Brentjens, MD, PhD, deputy director and chair of medicine at the Roswell Park Comprehensive Cancer Center, discusses:
- How he has seen the field evolve since its inception, and what excites him most about its future
- How the Roswell Park expansion helps improve patient access to CAR T-cell therapy
- The key safety concerns associated with CAR T-cell therapy, along with how Roswell Park aims to mitigate potential risks
- How Roswell Park is working to make CAR T-cell therapy more widely available
- The steps needed to be taken at the regulatory and healthcare policy levels in order to support the broader adoption of CAR T-cell therapy
The latest episode of The Pharmaceutical Commerce Podcast is available directly on Audioboom, Spotify, or iHeart.
Related Content:
